Shamlal Tekwani, MD
Ophthalmology · Saint Louis, MONPI 1962472480
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 54 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 16 manufacturers, the largest accounting for just 20.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $984 and has fallen 88.3% since, to $115 in 2024.
Across 54 payments — averaging $33.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$357
- Bausch & Lomb Americas Inc.$288
- Mallinckrodt Hospital Products Inc.$246
- Alcon$206
- Dompe US, Inc.$122
- Genentech USA, Inc.$110
- plus $455 from 10 others
What the payments were for
- Food & beverage$1,77399%
- Education$101%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 14 | $357 |
| Bausch & Lomb Americas Inc. | 6 | $288 |
| Mallinckrodt Hospital Products Inc. | 6 | $246 |
| Alcon | 6 | $206 |
| Dompe US, Inc. | 1 | $122 |
| Genentech USA, Inc. | 1 | $110 |
| Sun Pharmaceutical Industries Inc. | 6 | $108 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $102 |
| Thea Pharma Inc. | 3 | $58 |
| Alimera Sciences, Inc. | 3 | $44 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $35 |
| Regeneron Healthcare Solutions, Inc. | 1 | $34 |
| Kala Pharmaceuticals, Inc. | 1 | $23 |
| Novartis | 1 | $18 |
| Spark Therapeutics, Inc. | 1 | $16 |
| Amgen | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,783 in reported general payments places this provider in the 55th percentile of 286 ophthalmology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 140 | $94,745 |
| XiidraLifitegrast | 75 | $66,805 |
| LumiganBimatoprost | 80 | $31,516 |
| Cyclosporine | 73 | $24,332 |
| RocklatanNetarsudil Mesylat/Latanoprost | 52 | $17,673 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 75 | $14,849 |
| Travoprost | 69 | $6,647 |
| Alphagan PBrimonidine Tartrate | 19 | $5,968 |
| ProlensaBromfenac Sodium | 16 | $5,653 |
| Latanoprost | 809 | $5,161 |
| Travatan ZTravoprost | 18 | $4,668 |
| Brimonidine Tartrate | 95 | $4,180 |
| AzoptBrinzolamide | 11 | $3,924 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 258 | $3,299 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 26 | $1,806 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Alphagan P | $357 | $132,229239 claims |
| Bausch & Lomb Americas Inc.Xiidra | $288 | $66,80575 claims |
| AlconSimbrinza, Azopt | $206 | $18,77486 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $102 | $5,65316 claims |
| NovartisTravatan Z | $18 | $4,66818 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 286 ophthalmology providers in Missouri.
Other ophthalmology in Saint Louis
- Ranjan MalhotraSaint Louis$809K
- Gregg BerdySaint Louis$360K
- Rajendra ApteSaint Louis$112K
- Ian PithaSaint Louis$85K
- Senthil KrishnasamySaint Louis$46K
- Navin TekwaniSaint Louis$34K
- Steven LeeSaint Louis$33K
- John GalanisSaint Louis$20K
- Bruce CohenSaint Louis$11K
- Waseem AnsariSaint Louis$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.